Literature DB >> 15502102

Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor.

Juergen R Schaefer, Alexander M Sattler, Bastian Hackler, Bilgen Kurt, Rolf Hackler, Bernhard Maisch, Muhidien Soufi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15502102     DOI： 10.1373/clinchem.2004.037689

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  9 in total

1.  Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly.

Authors:  Juergen R Schaefer
Journal:  Eur J Hum Genet       Date:  2008-11-26       Impact factor: 4.246

2.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.

Authors:  Christophe Marçais; Bruno Verges; Sybil Charrière; Valérie Pruneta; Micheline Merlin; Stéphane Billon; Laurence Perrot; Jocelyne Drai; Agnès Sassolas; Len A Pennacchio; Jamila Fruchart-Najib; Jean-Charles Fruchart; Vincent Durlach; Philippe Moulin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 3.  Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology.

Authors:  Jaroslav A Hubacek
Journal:  Gene       Date:  2016-08-02       Impact factor: 3.688

4.  Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents.

Authors:  D D V Brito; A P Fernandes; K B Gomes; F F Coelho; N G Cruz; A P Sabino; J E Cardoso; P P Figueiredo-Filho; R Diamante; C R Norton; M O Sousa
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

5.  Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke.

Authors:  Anita Maász; Péter Kisfali; Zoltán Szolnoki; Ferenc Hadarits; Béla Melegh
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

6.  The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.

Authors:  Peter Henneman; Femke van der Sman-de Beer; Payman Hanifi Moghaddam; Petra Huijts; Anton F H Stalenhoef; John J P Kastelein; Cornelia M van Duijn; Louis M Havekes; Rune R Frants; Ko Willems van Dijk; Augustinus H M Smelt
Journal:  Eur J Hum Genet       Date:  2008-11-26       Impact factor: 4.246

7.  Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the apolipoprotein A5 gene.

Authors:  D Evans; A Bode; G von der Lippe; F U Beil; W A Mann
Journal:  Eur J Med Res       Date:  2011-02-24       Impact factor: 2.175

8.  Allelic drop-out may occur with a primer binding site polymorphism for the commonly used RFLP assay for the -1131T>C polymorphism of the Apolipoprotein AV gene.

Authors:  Kirsten J Ward; Sian Ellard; Chittaranjan S Yajnik; Timothy M Frayling; Andrew T Hattersley; Prathyusha N S Venigalla; Giriraj R Chandak
Journal:  Lipids Health Dis       Date:  2006-05-02       Impact factor: 3.876

9.  Phenotypic severity in a family with MEND syndrome is directly associated with the accumulation of potentially functional variants of cholesterol homeostasis genes.

Authors:  María Carmen Barboza-Cerda; Oralia Barboza-Quintana; Gerardo Martínez-Aldape; Raquel Garza-Guajardo; Miguel Angel Déctor
Journal:  Mol Genet Genomic Med       Date:  2019-08-08       Impact factor: 2.183
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.